Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
Mark Crowther shared a noteworthy post honoring Dr. Davide Matino, faculty member of McMaster University Department of Medicine, on LinkedIn:
“Incredible breakthroughs are happening right here in Hamilton – and McMaster University is at the heart of it.
A promising new hemophilia treatment – described as “life-transforming”- is being tested on local patients, bringing hope to thousands across Canada.
Leading this cutting-edge clinical trial is Dr. Davide Matino, a faculty member in McMaster University Department of Medicine, which boasts decades of global research excellence in hemostasis and thrombosis.
This isn’t just a milestone in medicine-it’s a powerful reminder of the impact academic research can have when paired with compassion and collaboration.
McMaster’s Faculty of Health Sciences continues to lead the way in advancing care and improving lives, both locally and globally.”
Read more about this exciting development here.
Stay uptaded on hematology world news with Hemostasis Today:
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial